Precision BioSciences, Inc.

DTIL · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders8.0%

Institutions68.7%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$34.26M	$68.70M	$25.10M	$115.53M	$24.29M	$22.24M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$52.15M	-$26.16M	-$100.37M	-$39.40M	-$109.83M	-$87.20M
Operating income as a percentage of revenue.	-152.2%	-38.1%	-399.9%	-34.1%	-452.2%	-392.1%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$45.72M	$7.17M	-$111.64M	-$30.60M	-$109.01M	-$92.88M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.56	$1.05	$-1.27	$-0.52	$-2.09	$-2.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.56	$1.04	$-1.27	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$110.82M	$85.90M	$189.58M	$143.66M	$89.80M	$180.89M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$154.42M	$136.39M	$238.17M	$211.50M	$150.16M	$235.23M
Everything the company owes — debt, unpaid bills, and other obligations.	$62.17M	$80.00M	$177.74M	$120.33M	$105.73M	$96.92M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$92.25M	$56.39M	$60.43M	$91.17M	$44.42M	$138.31M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$65.84M	-$58.45M	-$45.75M	-$10.85M	-$87.39M	-$71.02M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$85000	$250000	$3.32M	$5.05M	$5.03M	$24.67M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$65.93M	-$58.70M	-$49.07M	-$15.91M	-$92.42M	-$95.68M

Precision BioSciences, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison